Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Quantum Genomics Société Anonyme

DB:2QG
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2QG
DB
€38M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
  • Quantum Genomics Société Anonyme has significant price volatility in the past 3 months.
2QG Share Price and Events
7 Day Returns
-1.4%
DB:2QG
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-61.2%
DB:2QG
-7.4%
DE Biotechs
-14.2%
DE Market
2QG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Quantum Genomics Société Anonyme (2QG) -1.4% -13.1% -38.1% -61.2% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 2QG underperformed the Biotechs industry which returned -7.4% over the past year.
  • 2QG underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
2QG
Industry
5yr Volatility vs Market

2QG Value

 Is Quantum Genomics Société Anonyme undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Quantum Genomics Société Anonyme. This is due to cash flow or dividend data being unavailable. The share price is €2.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Quantum Genomics Société Anonyme's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Quantum Genomics Société Anonyme's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2QG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.50
ENXTPA:ALQGC Share Price ** ENXTPA (2020-04-08) in EUR €2.04
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Quantum Genomics Société Anonyme.

DB:2QG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALQGC Share Price ÷ EPS (both in EUR)

= 2.04 ÷ -0.50

-4.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Quantum Genomics Société Anonyme is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Quantum Genomics Société Anonyme is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Quantum Genomics Société Anonyme's expected growth come at a high price?
Raw Data
DB:2QG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Quantum Genomics Société Anonyme, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Quantum Genomics Société Anonyme's assets?
Raw Data
DB:2QG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €0.56
ENXTPA:ALQGC Share Price * ENXTPA (2020-04-08) in EUR €2.04
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:2QG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALQGC Share Price ÷ Book Value per Share (both in EUR)

= 2.04 ÷ 0.56

3.62x

* Primary Listing of Quantum Genomics Société Anonyme.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Quantum Genomics Société Anonyme is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Quantum Genomics Société Anonyme's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Quantum Genomics Société Anonyme has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2QG Future Performance

 How is Quantum Genomics Société Anonyme expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-59%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Quantum Genomics Société Anonyme expected to grow at an attractive rate?
  • Unable to compare Quantum Genomics Société Anonyme's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Quantum Genomics Société Anonyme's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Quantum Genomics Société Anonyme's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2QG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2QG Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts -59%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2QG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2QG Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 16 1
2020-12-31 8 -11 3
2020-04-09
DB:2QG Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 -11 -9
2019-09-30 -9
2019-06-30 -12 -10
2019-03-31 -11 -11
2018-12-31 -11 -12
2018-09-30 0 -12
2018-06-30 0 -10 -12
2018-03-31 0 -9 -10
2017-12-31 -8 -9
2017-09-30 0 -8
2017-06-30 0 -6 -7
2017-03-31 0 -6 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Quantum Genomics Société Anonyme is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Quantum Genomics Société Anonyme is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2QG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Quantum Genomics Société Anonyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2QG Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -1.70 -1.70 -1.70 1.00
2020-12-31 -0.61 -0.61 -0.61 1.00
2020-04-09
DB:2QG Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.50
2019-09-30 -0.53
2019-06-30 -0.59
2019-03-31 -0.65
2018-12-31 -0.76
2018-09-30 -0.75
2018-06-30 -1.00
2018-03-31 -0.91
2017-12-31 -0.85
2017-09-30 -0.72
2017-06-30 -0.75
2017-03-31 -0.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Quantum Genomics Société Anonyme will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Quantum Genomics Société Anonyme's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Quantum Genomics Société Anonyme has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2QG Past Performance

  How has Quantum Genomics Société Anonyme performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Quantum Genomics Société Anonyme's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Quantum Genomics Société Anonyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Quantum Genomics Société Anonyme's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Quantum Genomics Société Anonyme's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Quantum Genomics Société Anonyme's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Quantum Genomics Société Anonyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2QG Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -9.08 1.73
2019-09-30 -9.49 2.25
2019-06-30 -9.91 2.77
2019-03-31 -10.95 2.59
2018-12-31 -11.99 2.40
2018-09-30 0.00 -11.77 2.39
2018-06-30 0.00 -11.55 2.39
2018-03-31 0.00 -10.47 2.42
2017-12-31 -9.38 2.46
2017-09-30 0.00 -7.95 2.25
2017-06-30 0.00 -6.53 2.04
2017-03-31 0.00 -5.88 1.93
2016-12-31 -5.24 1.82
2016-09-30 0.00 -4.99 1.79
2016-06-30 0.01 -4.73 1.76
2016-03-31 0.08 -4.25 1.68
2015-12-31 0.14 -3.76 1.60
2015-09-30 0.26 -3.24 1.48
2015-06-30 0.38 -2.71 1.35
2015-03-31 0.35 -2.46 1.33
2014-12-31 0.32 -2.21 1.30
2014-09-30 0.21 -2.15 1.27
2014-06-30 0.09 -2.09 1.24
2014-03-31 0.06 -1.82 1.00
2013-12-31 0.02 -1.54 0.76

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Quantum Genomics Société Anonyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Quantum Genomics Société Anonyme has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Quantum Genomics Société Anonyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Quantum Genomics Société Anonyme's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Quantum Genomics Société Anonyme has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2QG Health

 How is Quantum Genomics Société Anonyme's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Quantum Genomics Société Anonyme's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Quantum Genomics Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Quantum Genomics Société Anonyme's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Quantum Genomics Société Anonyme's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 10290.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Quantum Genomics Société Anonyme Company Filings, last reported 3 months ago.

DB:2QG Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 10.17 0.00 11.16
2019-09-30 10.17 0.00 11.16
2019-06-30 11.10 0.00 11.63
2019-03-31 11.10 0.00 11.63
2018-12-31 11.87 0.00 14.80
2018-09-30 11.87 0.00 14.80
2018-06-30 3.29 0.00 5.97
2018-03-31 3.29 0.00 5.97
2017-12-31 8.87 0.00 11.09
2017-09-30 8.87 0.00 11.09
2017-06-30 6.69 0.00 7.32
2017-03-31 6.69 0.00 7.32
2016-12-31 10.52 0.00 11.20
2016-09-30 10.52 0.00 11.20
2016-06-30 13.03 0.00 13.22
2016-03-31 13.03 0.00 13.22
2015-12-31 8.02 0.00 8.65
2015-09-30 8.02 0.00 8.65
2015-06-30 11.01 0.00 10.15
2015-03-31 11.01 0.00 10.15
2014-12-31 -0.13 3.31 3.32
2014-09-30 -0.13 3.31 3.32
2014-06-30 0.76 0.19 1.08
2014-03-31 0.76 0.19 1.08
2013-12-31 -1.63 1.05 0.33
  • Quantum Genomics Société Anonyme's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Quantum Genomics Société Anonyme had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Quantum Genomics Société Anonyme has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Quantum Genomics Société Anonyme has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Quantum Genomics Société Anonyme's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Quantum Genomics Société Anonyme has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2QG Dividends

 What is Quantum Genomics Société Anonyme's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Quantum Genomics Société Anonyme dividends. Estimated to be 0% next year.
If you bought €2,000 of Quantum Genomics Société Anonyme shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Quantum Genomics Société Anonyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Quantum Genomics Société Anonyme's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2QG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2QG Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 2.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Quantum Genomics Société Anonyme has not reported any payouts.
  • Unable to verify if Quantum Genomics Société Anonyme's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Quantum Genomics Société Anonyme's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Quantum Genomics Société Anonyme has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Quantum Genomics Société Anonyme's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Quantum Genomics Société Anonyme's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Quantum Genomics Société Anonyme afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Quantum Genomics Société Anonyme has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2QG Management

 What is the CEO of Quantum Genomics Société Anonyme's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jean-Philippe Milon
AGE 59
TENURE AS CEO 2 years
CEO Bio

Dr. Jean-Philippe Milon, PhD., has been the Chief Executive Officer at Quantum Genomics Société Anonyme since April 06, 2018 and has been its Director since June 27, 2019. Dr. Milon served as the Chief Operating Officer of Quantum Genomics Société Anonyme until April 2018. Dr. Milon was responsible for the business development strategy of whose objective is to conclude, during phase 2, a partnership agreement with a pharmaceutical company regarding QGC001, its first in class drug candidate for the treatment of hypertension at Quantum Genomics. He is an Operating Partner of 21 Invest France and has been its Member of Supervisory Board since December 2018. Dr. Milon served in various management positions at local and international level at Bayer where he was involved in primary care and cardiology, led the global operations of mergers and acquisitions, licensing and business development. He was the CEO of Bayer Healthcare France. Additionally he managed the cardiovascular franchise of Sandoz. Dr. Milon served as Director of Operations at Quantum Genomics SA.

CEO Compensation
  • Insufficient data for Jean-Philippe to compare compensation growth.
  • Insufficient data for Jean-Philippe to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Quantum Genomics Société Anonyme management team in years:

2
Average Tenure
  • The tenure for the Quantum Genomics Société Anonyme management team is about average.
Management Team

Lionel Ségard

TITLE
Founder & Chairman
COMPENSATION
€244K
AGE
51

Jean-Philippe Milon

TITLE
CEO & Director
AGE
59
TENURE
2 yrs

Benoît Gueugnon

TITLE
Chief Financial Officer
TENURE
0.3 yrs

Bruno Besse

TITLE
Chief Medical Officer
TENURE
3 yrs
Board of Directors Tenure

Average tenure and age of the Quantum Genomics Société Anonyme board of directors in years:

3.5
Average Tenure
59.5
Average Age
  • The tenure for the Quantum Genomics Société Anonyme board of directors is about average.
Board of Directors

Jean-Philippe Milon

TITLE
CEO & Director
AGE
59
TENURE
0.8 yrs

Christian Béchon

TITLE
Director
AGE
60

Lionel Ségard

TITLE
Founder & Chairman
COMPENSATION
€244K
AGE
51

Mark Caulfield

TITLE
Member of Scientific & Clinical Advisory Board

Alexandre Persu

TITLE
Member of Scientific & Clinical Advisory Board

Keith Ferdinand

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
4.2 yrs

Henry Black

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
4.2 yrs

Howard Dittrich

TITLE
Member of Scientific & Clinical Advisory Board
AGE
65
TENURE
4.2 yrs

Toshiro Fujita

TITLE
Member of Scientific and Clinical Advisory Board
TENURE
2.8 yrs

Frans Leenen

TITLE
Member of Scientific and clinical advisory board
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Quantum Genomics Société Anonyme's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Quantum Genomics Société Anonyme has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2QG News

Simply Wall St News

2QG Company Info

Description

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug for the treatment of hypertension and heart failure, as well as acts on the inhibition of Aminopeptidase A in the brain. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company is based in Paris, France.

Details
Name: Quantum Genomics Société Anonyme
2QG
Exchange: DB
Founded:
€37,979,748
18,617,524
Website: http://www.quantum-genomics.com
Address: Quantum Genomics Société Anonyme
33, rue Marbeuf,
Paris,
Ile-de-France, 75008,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALQGC Ordinary Shares Euronext Paris FR EUR 29. Jul 2009
DB 2QG Ordinary Shares Deutsche Boerse AG DE EUR 29. Jul 2009
BST 2QG Ordinary Shares Boerse-Stuttgart DE EUR 29. Jul 2009
LSE 0D1J Ordinary Shares London Stock Exchange GB EUR 29. Jul 2009
Number of employees
Current staff
Staff numbers
12
Quantum Genomics Société Anonyme employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:12
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/04
Last earnings filing: 2020/03/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.